Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Cash & Equivalents (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Cash & Equivalents for 16 consecutive years, with $319031.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 43.13% to $319031.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $319031.0, a 43.13% decrease, with the full-year FY2025 number at $319031.0, down 43.13% from a year prior.
  • Cash & Equivalents was $319031.0 for Q4 2025 at Cryo Cell International, up from $265207.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $11.3 million in Q1 2021 to a low of $137491.0 in Q2 2025.
  • A 5-year average of $2.5 million and a median of $853997.0 in 2023 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 38.14% in 2024; the steepest drop was 82.0% in 2024.
  • Cryo Cell International's Cash & Equivalents stood at $8.3 million in 2021, then crashed by 79.38% to $1.7 million in 2022, then tumbled by 76.17% to $406067.0 in 2023, then skyrocketed by 38.14% to $560960.0 in 2024, then plummeted by 43.13% to $319031.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Cash & Equivalents are $319031.0 (Q4 2025), $265207.0 (Q3 2025), and $137491.0 (Q2 2025).